Evidence map›Paper›PMID 37483849›Full record

ArticleCentral European journal of urology2023

The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer.

Francesco Chierigo, Rocco Simone Flammia, Gabriele Sorce, Benedikt Hoeh, Lukas Hohenhorst, Zhe Tian, Fred Saad, Michele Gallucci, Alberto Briganti, Francesco Montorsi and 9 more

Open access · greenAbstract read
In one paragraph

Article in Central European journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Association between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer following Radical Prostatectomy: A Systematic Review.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024
    Pooled it
  2. C-reactive protein-albumin-lymphocyte index predicts biochemical recurrence in prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 5 countries.

Francesco ChierigoDepartment of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
Rocco Simone FlammiaCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Centre, Montréal, Québec, Canada.
Gabriele SorceCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Centre, Montréal, Québec, Canada.
Benedikt HoehCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Centre, Montréal, Québec, Canada.
Lukas HohenhorstCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Centre, Montréal, Québec, Canada.
Zhe TianCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Centre, Montréal, Québec, Canada.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Centre, Montréal, Québec, Canada.
Michele GallucciDepartment of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy.
Alberto BrigantiDivision of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesco MontorsiDivision of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Felix K H ChunDepartment of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Markus GraefenMartini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
Giovanni GuanoDepartment of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
Guglielmo ManticaDepartment of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
Marco BorghesiDepartment of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
Nazareno SuardiDepartment of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
Carlo TerroneDepartment of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Centre, Montréal, Québec, Canada.
University of Genoa · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversité de Montréal · CAPoliclinico Umberto I · ITGoethe University Frankfurt · DEUniversität Hamburg · DEUniversity Hospital Frankfurt · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The aim of this study was to assess the association between the type and number of D'Amico high-risk criteria (DHRCs) with rates of pathologically non-organ-confined (NOC) prostate cancer in patients treated with radical prostatectomy (RP) and pelvic lymphadenectomy (PLND). Material and methods: In the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 12961 RP and PLDN patients with at least one DHRC. We relied on descriptive statistics and multivariable logistic regression models. Results: Of 12 961 patients, 6135 (47%) exclusively harboured biopsy Gleason score (GS) 8-10, 3526 (27%) had clinical stage ≥T2c, and 1234 (9.5%) had prostate-specific antigen (PSA) >20 ng/mL. Only 1886 (15%) harboured any combination of 2 DHRCs. Finally, all 3 DHRCs were present in 180 (1.4%) patients. NOC rates increased from 32% for clinical T stage ≥T2c to 49% for either GS 8-10 only or PSA >20 ng/mL only and to 66-68% for any combination of 2 DHRCs, and to 84% for respectively all 3 DHRCs, which resulted in a multivariable logistic regression OR of 1.00, 2.01 (95% CI 1.85-2.19; p <0.001), 4.16 (95% CI 3.69-4.68; p <0.001), and 10.83 (95% CI 7.35-16.52; p <0.001), respectively. Conclusions: Our study indicates a stimulus-response effect according to the type and number of DHRCs. Hence, a formal risk-stratification within high-risk prostate cancer patients should be considered in clinical decision-making.

Indexed as

high-risk prostate cancernon-organ-confinedprostatectomySEERstaging

Identifiers

PMID37483849
PMCPMC10357822
OpenAlexW4367483933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.